Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the winners of its 13th annual Regeneron Prize for Creative Innovation. The 2025 recipients are Dr. Alissandra L. Hillis from MIT and Sreekar Mantena from Harvard Medical School-MIT, each receiving $50,000 awards plus $5,000 institutional grants.
Dr. Hillis's research focuses on cancer cell metabolism and proposed studying endometriosis, while Mr. Mantena's work involves investigating thymus cell competence decline with age. Seven other finalists received $5,000 awards. Since 2013, the program has provided nearly $2 million in awards to early-career scientists, with Regeneron's STEM initiatives reaching over 3.25 million students since 2020.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato i vincitori del suo 13° Premio annuale Regeneron per l'Innovazione Creativa. I destinatari del 2025 sono la Dott.ssa Alissandra L. Hillis del MIT e Sreekar Mantena della Harvard Medical School-MIT, che riceveranno ciascuno premi di 50.000$ oltre a sovvenzioni istituzionali di 5.000$.
La ricerca della Dott.ssa Hillis si concentra sul metabolismo delle cellule tumorali e include uno studio proposto sull'endometriosi, mentre il lavoro di Mantena riguarda l'indagine sul declino della competenza delle cellule del timo con l'età. Altri sette finalisti hanno ricevuto premi di 5.000$. Dal 2013, il programma ha assegnato quasi 2 milioni di dollari a scienziati alle prime armi, con le iniziative STEM di Regeneron che hanno raggiunto oltre 3,25 milioni di studenti dal 2020.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado a los ganadores de su 13º Premio anual Regeneron a la Innovación Creativa. Los galardonados de 2025 son la Dra. Alissandra L. Hillis del MIT y Sreekar Mantena de la Harvard Medical School-MIT, quienes recibirán premios de 50.000$ cada uno, además de subvenciones institucionales de 5.000$.
La investigación de la Dra. Hillis se centra en el metabolismo de las células cancerosas y propone estudiar la endometriosis, mientras que el trabajo de Mantena investiga el declive de la competencia de las células del timo con la edad. Otros siete finalistas recibieron premios de 5.000$. Desde 2013, el programa ha otorgado casi 2 millones de dólares a científicos en etapas iniciales, y las iniciativas STEM de Regeneron han alcanzado a más de 3,25 millones de estudiantes desde 2020.
Regeneron Pharmaceuticals (NASDAQ: REGN)가 제13회 연례 Regeneron 창의적 혁신상을 발표했습니다. 2025년 수상자는 MIT의 Alissandra L. Hillis 박사와 Harvard Medical School-MIT의 Sreekar Mantena로, 각각 5만 달러 상금과 5천 달러의 기관 보조금을 받습니다.
Hillis 박사의 연구는 암세포 대사에 중점을 두고 있으며 자궁내막증 연구를 제안했으며, Mantena 씨의 연구는 나이에 따른 흉선 세포 기능 저하를 조사합니다. 다른 7명의 최종 후보자들도 각각 5천 달러의 상금을 받았습니다. 2013년부터 이 프로그램은 초기 경력 과학자들에게 거의 200만 달러의 상금을 제공했으며, Regeneron의 STEM 이니셔티브는 2020년 이후 325만 명 이상의 학생에게 도달했습니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a annoncé les lauréats de son 13e Prix annuel Regeneron pour l'Innovation Créative. Les récipiendaires 2025 sont Dr Alissandra L. Hillis du MIT et Sreekar Mantena de la Harvard Medical School-MIT, chacun recevant des prix de 50 000 $ ainsi que des subventions institutionnelles de 5 000 $.
La recherche du Dr Hillis porte sur le métabolisme des cellules cancéreuses et propose d'étudier l'endométriose, tandis que les travaux de M. Mantena portent sur le déclin de la compétence des cellules du thymus avec l'âge. Sept autres finalistes ont reçu des prix de 5 000 $. Depuis 2013, le programme a attribué près de 2 millions de dollars à des scientifiques en début de carrière, et les initiatives STEM de Regeneron ont touché plus de 3,25 millions d'étudiants depuis 2020.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat die Gewinner seines 13. jährlichen Regeneron-Preises für kreative Innovation bekannt gegeben. Die Preisträger 2025 sind Dr. Alissandra L. Hillis vom MIT und Sreekar Mantena von der Harvard Medical School-MIT, die jeweils 50.000$ sowie institutionelle Zuschüsse von 5.000$ erhalten.
Dr. Hillis' Forschung konzentriert sich auf den Stoffwechsel von Krebszellen und schlägt vor, Endometriose zu untersuchen, während Mantenas Arbeit den altersbedingten Abbau der Thymuszellkompetenz untersucht. Sieben weitere Finalisten erhielten jeweils 5.000$ Preise. Seit 2013 hat das Programm nahezu 2 Millionen Dollar an Nachwuchswissenschaftler vergeben, und Regenerons STEM-Initiativen haben seit 2020 über 3,25 Millionen Schüler erreicht.
- None.
- None.
TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research.
Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and pitch their “dream projects” in biomedical science to a panel of Regeneron’s leading scientists, who evaluate the proposals for scientific merit, creativity and originality.
This year’s winners are Alissandra L. Hillis, Ph.D., and Sreekar Mantena. Dr. Hillis is a postdoctoral fellow at the Massachusetts Institute of Technology (MIT), and Mr. Mantena is an M.D.-Ph.D. candidate, enrolled in the joint Harvard Medical School-MIT program and nominated by Broad Institute. Each winner has been awarded
“Regeneron has changed the practice of medicine by dreaming big and inventing game-changing technologies – from the soluble receptor technology that helps save the vision of millions, to the VelocImmune® humAb mouse that enabled treatments helping people suffering from allergic diseases and cancer,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron, and principal inventor of Regeneron’s 12 FDA-approved medicines. “The Regeneron Prize encourages young scientists to dream big, challenge what’s possible, and recognize their potential to bring forward the breakthroughs of tomorrow. That’s exactly the kind of thinking the world needs right now, and we are proud to play a small part in the promising careers of these winners and finalists.”
Dr. Hillis works in the lab of Professor Matthew Vander Heiden, Director of the Koch Institute at MIT, studying aspects of metabolism that are limiting for cell proliferation in different contexts in order to translate findings in cancer cell metabolism into novel cancer therapies. Dr. Hillis proposed an exciting approach to study endometriosis, a highly prevalent condition in women that causes significant medical consequences, including chronic pain.
Mr. Mantena is currently in the lab of Professor Soumya Raychaudhuri at Brigham and Women’s Hospital applying single-cell genomics approaches to study the adaptive immune system. For his proposal, Mr. Mantena was intrigued by the interesting phenomenon that cells in our thymus, which is responsible for important aspects of immune function, decrease competence with age. He wants to better understand this and proposed some exciting approaches to unravel this biological process and understand its implications for disease.
"The Regeneron Prize prompts early career scientists to solve a problem that is important to them. We look for originality and creativity on the one hand, and practicality on the other. In particular, we’re trying to find young scientists who ask scientifically and medically important questions, alongside the ability to design a research plan capable of answering those questions," said David J. Glass, M.D., Vice President of Research, and Chair of the Postdoctoral Program at Regeneron.
Inspiring and preparing young people to pursue STEM careers is a core focus of Regeneron’s social impact work. Founded and led by physician-scientists, Regeneron is deeply committed to advancing the next generation of innovators who will tackle society’s toughest challenges. Since its inception in 2013, the Regeneron Prize has provided nearly
Requests for applications for the Regeneron Prize are distributed to academic institutions each December. Regeneron asks institutions to nominate two graduate students and two postdoctoral fellows. In addition to the dream project proposals, submissions must include a curriculum vitae and samples of publications that enable the selection committee to review each nominee's scholarly productivity. For more information, please email science.education@regeneron.com.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono and matching gift programs. Our most significant philanthropic commitments are in the area of early science education, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Media Contacts:
Tara Naugle, Regeneron
914-648-9917
Tara.Naugle@Regeneron.com
FAQ
Who won the 2025 Regeneron Prize for Creative Innovation?
What is the Regeneron Prize for Creative Innovation?
How much is the Regeneron Prize award worth?
What research did the 2025 Regeneron Prize winners propose?
How can scientists apply for the Regeneron Prize?
